Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of V501 (Gardasil) Given Concomitantly with Menactra and Adacel in Adolescents
NCT00325130Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2006
- Primary completion
- Apr 2007
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Merck & Co.. Started Apr 2006; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT00325130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00325130.